In addition, malignant cells may induce an immunosuppressive microenvironment due to greater interactions with T cells presenting exhausted characteristics through ligand‐receptor pairs such as TNF‐ICOS, indicating that blocking TNF‐ICOS binding may affect the interaction of CD4+ Tregs with malignant cells and might be an effective therapeutic target for endometrial cancer (Figure 3F). This evidence concerns the gene TNF and endometrial cancer.